Trials Offered by a Specific Doctor

Naiyer Rizvi, MD

Dr. Rizvi is the director of thoracic oncology and director of immunotherapeutics for the division of Hematology and Oncology at Columbia University Medical Center.

He also holds the Price Chair in Clinical Translational Research.

He is an internationally recognized leader in the treatment of lung cancer and immunotherapy drug development. Prior to joining Columbia University Medical Center, his clinical research at Memorial Sloan Kettering Cancer played a significant role in the FDA approval path of a new class of immunotherapies, called immune checkpoint inhibitors, for melanoma and lung cancer.

His research focus is studying mechanisms of sensitivity and resistance to immunotherapy. Through genetic testing of tumors, he has been able to improve the understanding of why immune checkpoint inhibitors work in certain patients. This work has been partially supported by Stand Up To Cancer -- Cancer Research Institute Immunology funding.

In his research, he also is studying why certain cancers do not respond to immune checkpoint inhibitors, so we can find better ways to harness the immune system to attack cancer cells. He oversees phase 1 immunotherapy research in solid tumors at Columbia University Medical Center and is conducting key clinical studies of novel immunotherapy drugs and immunotherapy combinations to help more patients in the fight against cancer.

Clinical Studies Managed By Dr. Rizvi:
More InfoTitleSponsorIRB Number
DetailsA study for patients with advanced refractory solid tumors using study drug VarlilumabEli Lilly and CompanyAAAO7762
Details[CLOSED] Study for patients with melanoma, non-small cell lung cancer (NSCLC) or squamous cell cancer of the head and neck (SCCHN) using drug B7-H3MacroGenics, IncAAAP0812
DetailsStudy for patients with advanced Non-small Cell Lung Cancer using study drug MEDI4736MedImmuneAAAP0151
DetailsA study for patients with advanced cancers using study drug LAG525NovartisAAAP4008
Details[CLOSED] A study for patients with advanced Non-Small-Cell Lung Cancer (NSCLC) using study drug MEDI4736 in combination with TremelimumabAstraZenecaAAAP9838
DetailsA study to identify the benefits of study drug pembrolizumab in patients with advanced or recurrent cancersMerckAAAQ5450
DetailsA study for patients with advanced or recurrent solid tumors or lymphomas using study drug CX-072CytomX TherapeuticsAAAR1037